Free Trial

Yoshiyuki Aikawa Sells 3,100,000 Shares of SBC Medical Group (NASDAQ:SBC) Stock

SBC Medical Group logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • CEO Yoshiyuki Aikawa sold 3,100,000 shares on April 21 at an average price of $3.02 for proceeds of $9.36M, trimming his stake by 3.76% to 79,304,460 shares; he also sold 4,422,900 shares on March 6 at $2.12 (~$9.38M).
  • SBC shares traded around $3.40 with a market cap of about $348.8M, a P/E of 6.94, 50/200-day moving averages near $4.01/$4.02, and a 12-month range of $2.97–$5.75.
  • The company reported Q1 EPS of $0.14 (beating $0.13) but revenue missed at $39.6M versus $45.2M, and analysts hold a consensus rating of “Hold” with a $8.50 price target amid mixed buy/sell coverage.
  • MarketBeat previews the top five stocks to own by May 1st.

SBC Medical Group Holdings Incorporated (NASDAQ:SBC - Get Free Report) CEO Yoshiyuki Aikawa sold 3,100,000 shares of the firm's stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $3.02, for a total value of $9,362,000.00. Following the transaction, the chief executive officer owned 79,304,460 shares of the company's stock, valued at $239,499,469.20. The trade was a 3.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Yoshiyuki Aikawa also recently made the following trade(s):

  • On Friday, March 6th, Yoshiyuki Aikawa sold 4,422,900 shares of SBC Medical Group stock. The stock was sold at an average price of $2.12, for a total value of $9,376,548.00.

SBC Medical Group Stock Performance

Shares of SBC remained flat at $3.40 during trading hours on Thursday. The stock had a trading volume of 140,319 shares, compared to its average volume of 117,629. The company's 50-day moving average is $4.01 and its two-hundred day moving average is $4.02. The company has a quick ratio of 3.74, a current ratio of 3.78 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $348.77 million, a PE ratio of 6.94 and a beta of 0.99. SBC Medical Group Holdings Incorporated has a 12-month low of $2.97 and a 12-month high of $5.75.

SBC Medical Group (NASDAQ:SBC - Get Free Report) last posted its quarterly earnings results on Friday, March 27th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.01. The firm had revenue of $39.57 million during the quarter, compared to analyst estimates of $45.19 million. SBC Medical Group had a return on equity of 20.76% and a net margin of 29.37%. Research analysts anticipate that SBC Medical Group Holdings Incorporated will post 0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SBC Medical Group

Large investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. bought a new stake in SBC Medical Group in the 4th quarter worth about $49,000. Russell Investments Group Ltd. increased its holdings in SBC Medical Group by 292.0% in the 4th quarter. Russell Investments Group Ltd. now owns 11,775 shares of the company's stock worth $51,000 after buying an additional 8,771 shares in the last quarter. Nuveen LLC bought a new stake in SBC Medical Group in the 4th quarter worth about $53,000. Wells Fargo & Company MN increased its holdings in SBC Medical Group by 195.1% in the 4th quarter. Wells Fargo & Company MN now owns 12,626 shares of the company's stock worth $54,000 after buying an additional 8,348 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in SBC Medical Group in the 2nd quarter worth about $64,000. 60.82% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently issued reports on SBC. BTIG Research began coverage on SBC Medical Group in a research report on Friday, March 6th. They issued a "buy" rating and a $8.00 price target for the company. Weiss Ratings reiterated a "sell (d+)" rating on shares of SBC Medical Group in a report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $8.50.

View Our Latest Analysis on SBC Medical Group

SBC Medical Group Company Profile

(Get Free Report)

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company's primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in SBC Medical Group Right Now?

Before you consider SBC Medical Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SBC Medical Group wasn't on the list.

While SBC Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines